[Form 3] MEI Pharma, Inc. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Equinix (EQIX) filed a Form S-8 on 30 July 2025 to register an additional 3,300,000 shares of common stock (par $0.001), together with related options and rights, for issuance under its 2020 Equity Incentive Plan. Acting under General Instruction E, the company incorporates by reference its prior S-8 filed 18 June 2020 and subsequent Exchange Act reports, including the 2024 Form 10-K and 2025 Form 10-Qs/8-Ks. No new financial statements, capital raise, or amendments to plan terms are included. Equinix confirms its status as a large accelerated filer; Chief Legal Officer Kurt Pletcher supplies the legal opinion. Standard Delaware indemnification provisions, exhibit list, and powers of attorney accompany the filing. The registration expands share capacity for future employee equity awards but does not itself issue shares or impact current financial results.

Positive

• The filing ensures Equinix can continue granting equity, aiding talent retention and alignment between employees and shareholders.

Negative

• Registering 3.3 million additional shares expands the potential share count, introducing incremental dilution risk for existing holders when awards vest.

Insights

Equity Compensation Analyst

TL;DR – Routine S-8 adds 3.3 M shares for employee equity; neutral impact, mild future dilution risk.

The filing merely increases the number of shares available under the 2020 Equity Incentive Plan. Such routine shelf registration does not affect cash flow or operations and is common for large tech firms with ongoing hiring needs. While the extra 3.3 million shares raise the theoretical share count, dilution only occurs when awards vest. No change in plan terms, strike prices, or governance was disclosed, so investor impact is presently neutral.

Portfolio Manager

TL;DR – Maintains talent incentives; manageable dilution if exercised over time.

The additional share pool supports Equinix’s ability to attract and retain key staff in a competitive data-center market. Assuming staggered vesting, dilution should be incremental and offset by human-capital benefits. Because the filing does not trigger an immediate issuance or capital transaction, I view it as non-impactful for valuation models today, but I will monitor total shares outstanding in future 10-Qs.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lee Charles Benjamin

(Last) (First) (Middle)

9920 PACIFIC HEIGHTS BLVD., SUITE 150

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
07/22/2025

3. Issuer Name and Ticker or Trading Symbol
MEI Pharma, Inc. [ MEIP ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	292,397	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Justin J. File, as Attorney-in-fact for the Reporting Person	07/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many new shares did Equinix (EQIX) register in the July 30 2025 Form S-8?

Equinix registered 3,300,000 additional shares of common stock for its 2020 Equity Incentive Plan.

What is the purpose of Equinixs 2020 Equity Incentive Plan?

The plan provides stock options, RSUs and other equity awards to employees, directors and eligible consultants to align compensation with shareholder value.

Does this S-8 filing affect Equinixs current financial statements or cash position?

No. An S-8 only registers shares for future issuance; it does not impact income, cash flow or balance sheet at the time of filing.

Who issued the legal opinion for the registration statement?

Chief Legal Officer Kurt Pletcher provided the validity opinion for the shares being registered.

Which SEC reports are incorporated by reference into this Form S-8?

The filing incorporates the 2024 Form 10-K, 2025 Form 10-Qs for Q1 and Q2, and specified Form 8-Ks filed in 2025.

Will the registration immediately dilute existing EQIX shareholders?

No. Shares are only issued when equity awards are granted and vest; the S-8 itself does not create instant dilution.